Objective To investigate the effects of fosinopril and valsartan on the expression of intercellular adhesion molecule-1 (ICAM-1) and nitric oxide (NO) induced by oxidized low-density lipoprotein (ox-LDL) in human umbi...Objective To investigate the effects of fosinopril and valsartan on the expression of intercellular adhesion molecule-1 (ICAM-1) and nitric oxide (NO) induced by oxidized low-density lipoprotein (ox-LDL) in human umbilical vein endothelial cells.Methods The levels of NO, ICAM-1, and nitric oxide synthase (NOS) were determined using the nitrate reductase method, ELISA, immunohistochemical and image analyses.Results The ox-LDL can significantly increase the expression of ICAM-1 and inhibit the expression of NO and NOS in a dose-dependent manner. Fosinopril and valsartan can significantly inhibit these roles of ox-LDL. The roles of fosinopril and valsartan were not significantly different.Conclusion Fosinopril and valsartan inhibit oxidized LDL-induced expression of ICAM-1 and increase the expression of NO in human umbilical vein endothelial cells, which is one of the mechanisms of antiatherosclerosis.展开更多
目的探讨辛伐他汀联合α-硫辛酸、福辛普利对糖尿病肾病患者肾功能及糖脂代谢水平的影响。方法选取2021年4月至2023年4月郑州人民医院收治糖尿病肾病88例患者,采用随机数字表法分为两组,对照组44例采用α-硫辛酸、福辛普利治疗,观察组4...目的探讨辛伐他汀联合α-硫辛酸、福辛普利对糖尿病肾病患者肾功能及糖脂代谢水平的影响。方法选取2021年4月至2023年4月郑州人民医院收治糖尿病肾病88例患者,采用随机数字表法分为两组,对照组44例采用α-硫辛酸、福辛普利治疗,观察组44例采用辛伐他汀联合α-硫辛酸及福辛普利治疗,均在治疗后3个月后比较疗效及氧化应激指标丙二醛(malondialdehyde,MDA)及超氧化物歧化酶(superoxide dismutase,SOD)等水平的变化情况。结果两组治疗前糖化血红蛋白(HbA1c)、空腹血糖(fasting blood glucose,FPG)、餐后2 h血糖(2 h postprandial blood glucose,2 h PG)、低密度脂蛋白胆固醇(low density lipoprotein cholesterol,LDL-C)、甘油三酯(triglyceride,TG)、总胆固醇(total cholesterol,TC)水平比较差异无统计学意义(P>0.05),治疗后均降低,与治疗前比较有统计学意义(P<0.05),且观察组治疗后LDL-C及TG水平分别是(3.11±0.44)mmol/L和(1.09±0.21)mmol/L,均低于对照组(P<0.05),两组治疗后HbA1c、FPG、2 h PG及TC水平比较差异无统计学意义(P>0.05);两组治疗前肾功能比较差异无统计学意义(P>0.05),治疗8周后均降低,与治疗前比较有统计学意义(P<0.05),且观察组治疗后8周的24 h尿蛋白、血肌酐(Scr)及尿素氮(BUN)水平分别是(1.15±0.11)g/L、(177.48±8.54)μmol/L和(7.46±1.08)mmol/L,均低于对照组(P<0.05);两组治疗前氧化应激指标比较差异无统计学意义(P>0.05),治疗8周后观察组FMD及SOD水平分别为(14.48±2.23)%和(98.96±9.86)U/mL,高于对照组(P<0.05),观察组治疗8周后MDA水平(4.37±1.24)μmol/L,低于对照组(P<0.05)。结论糖尿病肾病患者进行α-硫辛酸联合福辛普利治疗,可改善肾功能,有效降低氧化应激水平。展开更多
文摘Objective To investigate the effects of fosinopril and valsartan on the expression of intercellular adhesion molecule-1 (ICAM-1) and nitric oxide (NO) induced by oxidized low-density lipoprotein (ox-LDL) in human umbilical vein endothelial cells.Methods The levels of NO, ICAM-1, and nitric oxide synthase (NOS) were determined using the nitrate reductase method, ELISA, immunohistochemical and image analyses.Results The ox-LDL can significantly increase the expression of ICAM-1 and inhibit the expression of NO and NOS in a dose-dependent manner. Fosinopril and valsartan can significantly inhibit these roles of ox-LDL. The roles of fosinopril and valsartan were not significantly different.Conclusion Fosinopril and valsartan inhibit oxidized LDL-induced expression of ICAM-1 and increase the expression of NO in human umbilical vein endothelial cells, which is one of the mechanisms of antiatherosclerosis.
文摘目的探讨辛伐他汀联合α-硫辛酸、福辛普利对糖尿病肾病患者肾功能及糖脂代谢水平的影响。方法选取2021年4月至2023年4月郑州人民医院收治糖尿病肾病88例患者,采用随机数字表法分为两组,对照组44例采用α-硫辛酸、福辛普利治疗,观察组44例采用辛伐他汀联合α-硫辛酸及福辛普利治疗,均在治疗后3个月后比较疗效及氧化应激指标丙二醛(malondialdehyde,MDA)及超氧化物歧化酶(superoxide dismutase,SOD)等水平的变化情况。结果两组治疗前糖化血红蛋白(HbA1c)、空腹血糖(fasting blood glucose,FPG)、餐后2 h血糖(2 h postprandial blood glucose,2 h PG)、低密度脂蛋白胆固醇(low density lipoprotein cholesterol,LDL-C)、甘油三酯(triglyceride,TG)、总胆固醇(total cholesterol,TC)水平比较差异无统计学意义(P>0.05),治疗后均降低,与治疗前比较有统计学意义(P<0.05),且观察组治疗后LDL-C及TG水平分别是(3.11±0.44)mmol/L和(1.09±0.21)mmol/L,均低于对照组(P<0.05),两组治疗后HbA1c、FPG、2 h PG及TC水平比较差异无统计学意义(P>0.05);两组治疗前肾功能比较差异无统计学意义(P>0.05),治疗8周后均降低,与治疗前比较有统计学意义(P<0.05),且观察组治疗后8周的24 h尿蛋白、血肌酐(Scr)及尿素氮(BUN)水平分别是(1.15±0.11)g/L、(177.48±8.54)μmol/L和(7.46±1.08)mmol/L,均低于对照组(P<0.05);两组治疗前氧化应激指标比较差异无统计学意义(P>0.05),治疗8周后观察组FMD及SOD水平分别为(14.48±2.23)%和(98.96±9.86)U/mL,高于对照组(P<0.05),观察组治疗8周后MDA水平(4.37±1.24)μmol/L,低于对照组(P<0.05)。结论糖尿病肾病患者进行α-硫辛酸联合福辛普利治疗,可改善肾功能,有效降低氧化应激水平。
